Login to Your Account

German Biotech: Where’s the Love?

By Cormac Sheridan
Staff Writer

Wednesday, September 4, 2013
MUNICH and HEIDELBERG, Germany – Biotech’s summer of love has been an overwhelmingly American affair. The flood of U.S. initial public offerings (IPOs) completed in 2013 – by the end of August, 26 companies had raised $1.84 billion – threatens to further widen the already large gulf between the U.S. and European biopharma sectors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription